Document is current

Article History

Received: 28 October 2024

Accepted: 14 March 2025

First Online: 4 April 2025

Declarations

:

: The study is being conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Guidelines for Good Clinical Practice and the local regulations. The study protocol was approved by the IEC of Hospital Universitari Vall D'Hebron on June 19th, 2023 (Ref: 2023/578) and the competent authorities of the European member states concerned (Spain: July 14th, 2023, France: October 10th, 2023, Italy: November 8th, 2023). All patients are providing written informed consent.

: Not applicable.

: RGC has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: AAA-Novartis, Advanz Pharma, Astellas, Bayer, BMS, Boehringer, Esteve, GSK, Hutchmed, Ipsen, ITM, MSD, PharmaMar, Pierre Fabre, Sanofi, Servier, Takeda.PJF has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from:  Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Takeda, Viatris.TW has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: Novartis, MSD, Esteve, Ipsen, ITM, Terumo, Pierre Fabre, Sanofi, OranoMed, Sirtex.CL has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: Pierre Fabre, AMGEN, Takeda, Ipsen, AAA.ED has received fees from AAA-Novartis, Janssen and GE.JCR has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: AMGEN, MSD, AAA.TV has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from from AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, Nordic Pharma, Novartis, Roche, Sirtex, Servier, Takeda. TV is a senior clinical investigator at the Research Foundation-Flanders (FWO), project number 1803723N.The remaining authors declare that they have no competing interests.GV has received a speaker’s fee from Pfizer, MSD, GSK and Pierre Fabrer, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics.TAG reports Advisory role or speaker &  fee from Lilly, Bayer, Johnson & Johnson, Astellas, Eisai, Roche, Ipsen, MSD  and Adacap. Research Grant from Johnson & Johnson and IPSEN.All the other co-authors confirmed that they had no competing interests to be declared.